- UroToday Home
- Urologic Oncology
Prostate Cancer Abstracts and Beyond
Recent Abstracts
-
Teleflex Announces Barrigel™ Rectal Spacer AI Model Now Available within Radformation AutoContouring SoftwareProstate CancerJuly 24, 2026
-
Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy.Prostate CancerJuly 24, 2026
-
Qualitative thematic analysis of online forum discussions on post-radiation prostate cancer survivorship.Prostate CancerJuly 24, 2026
-
A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.Prostate CancerJuly 24, 2026
-
Cellular plasticity and tumor ecosystem dynamics in prostate cancer: insights from single-cell and spatial transcriptomics.Prostate CancerJuly 24, 2026
-
Development of a prostate cancer survivorship care toolkit for Black men with clinical and contextual tailoring.Prostate CancerJuly 24, 2026
-
Prognostic Value of a Composite Score Incorporating Baseline [18F]FDG PET/CT and [68Ga]Ga-PSMA-11 PET/CT When Screening for [177Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).Prostate CancerJuly 23, 2026
-
Real-World Use of Prolaris® to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance.Prostate CancerJuly 23, 2026
-
Occupational exposure to metals and prostate cancer: CAPLIFE study.Prostate CancerJuly 23, 2026
-
Validation of AI-derived whole prostate volumetry versus ellipsoid formula for PSA density-based risk stratification.Prostate CancerJuly 23, 2026
Beyond the Abstracts
-
Early-access Use of Radioligand Therapy in Prostate Cancer - Beyond the AbstractProstate CancerJuly 23, 2026
-
Imaging Features That Predict Indeterminate Bone Lesion Outcomes on 18F-DCFPyL PSMA PET/CT Scan: A Multicenter Cohort of 42 Biopsy-Proven Lesions - Beyond the AbstractProstate CancerJuly 21, 2026
-
SBRT plus Abiraterone Acetate and ADT versus Abiraterone Acetate and ADT in Oligometastatic Castrate-Resistant Prostate Cancer (ARTO): Long-Term, Unplanned Overall Survival Analysis of an Open-Label, Randomised, Phase 2 Trial - Beyond the AbstractProstate CancerJuly 20, 2026
-
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer - Beyond the AbstractProstate CancerJuly 20, 2026
-
The Predictive Role of [177Lu]Lu-PSMA-617 SPECT/CT Semiquantitative Parameters from the 1st RLT Cycle in Advanced mCRPC: A Preliminary Bicentric Lesion-Based Analysis - Beyond the AbstractProstate CancerJuly 17, 2026
-
The Evolving PI-RADS Paradigm - Beyond the AbstractProstate CancerJuly 17, 2026
-
Same Target, Different Tools: A Multicenter Comparison of Local Anesthesia Cognitive Fusion, General Anesthesia Fusion, and General Anesthesia Grid Prostate Biopsy - Beyond the AbstractProstate CancerJuly 16, 2026
-
Intrafraction Motion Mitigation by Rectal Spacers in Prostate SBRT: Balloon, Hydrogel, and No-Spacer Comparison - Beyond the AbstractProstate CancerJuly 9, 2026
-
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer - Beyond the AbstractProstate CancerJuly 2, 2026
-
Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer - Beyond the AbstractProstate CancerJuly 2, 2026